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COMPARATIVE STUDY OF STEM CELL RECRUITMENT DURING 
POSTNATAL BONE FORMATION 
AMANDA MOLINELLI 
ABSTRACT 
Introduction: Post-natal fractures are among some of the most common orthopedic 
injuries with up to 10% resulting in delayed or non-unions.  Understanding the early 
mechanism of fracture repair via stem cell recruitment will allow for more specific 
therapeutics to be developed.  Two post-natal bone formation models were used for this 
study, ectopic bone and fracture repair; both show primarily endochondral ossification. 
To investigate the role of stem cells during post-natal bone formation, two markers were 
selected, based on previous results, Prx1 and Pax7. The Prx1 gene is expressed by 
skeletal progenitor cells within the periosteal tissues while the Pax7 gene is expressed by 
skeletal muscle precursor cells.  
Objectives: The purpose of this study is to follow stem cell lineages that arise from Prx1 
and Pax7 expressing cells in both ectopic bone growth and fracture repair models.  
Methods: Prx1 CreER-GFP mice (Kawanami et al., 2010) and Pax7 CreER (Jackson 
Laboratories) mice were individually crossed with the RosaAi14 reporter (dTomato) 
animal. These animals were then crossed with immunodeficient Rag1 mice allowing for 
implantation of human demineralized bone matrix. Six different control groups were 
analyzed with multiple mice used for each. These groups included no injury with 
Tamoxifen followed by three days (short term), seventeen days (intermediate) or 28 days 
and onward (long term) harvest, oil injections followed by three days (short term) or 30 
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days (long term) harvest, no injections, and Cre negative. Two methods of post-natal 
bone formation were studied, ectopic bone growth and fracture repair. For ectopic bone 
growth, demineralized bone matrix (DBM) was implanted on either the periosteum 
surface or and within skeletal muscle of the upper hind-limb. Samples were then 
harvested on day 16 or day 31 post-surgery. For post-natal fracture repair, mice received 
a transverse stabilized fracture and samples were harvested on day 5 or day 23. All 
samples were then fixed, decalcified, and standard frozen histology was performed.  
Images were collected with a fluorescent microscope to detect the presence of dTomato 
tagged Prx1 and Pax7 derived cells. Ratios of positive cells were calculated using total 
number of nuclei within the regions of interest.  
Results: Prx1 control animals that received no Tamoxifen injections showed about 4-
16% positively labeled cells. Cre+ control that received Tamoxifen washout showed the 
highest percentage of cells, 10-20%. Control animals that receive oil pulse and oil 
washout showed similar results, about 6-20%. Interestingly, the Cre- control group 
showed a high number of labeled cells, about 6-12%. Prx1 positive cells were seen 
throughout the bone (16-30%) and callous (43-70%) in the fracture model and throughout 
the bone (43%) and implant (30-47%) in the ectopic bone development model. Pax7 
control animals that received no tamoxifen injections and animals that received 
tamoxifen long term injections both showed the highest percentage of cells, 2% in the 
muscle. No response was seen in the bone or marrow for either of the control groups. No 
Pax7 derived cells were seen in the bone or callous in the fracture model or the bone and 
implant in the ectopic bone model.  
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Conclusions: Previous research has shown Prx1 cells to be localized to the periosteum. 
This study confirmed those results and showed an increase in Prx1 derived cells in the 
callous in the fracture model. An increase in Prx1 was also seen in the implant in the 
ectopic bone growth model. However, at a later time point, the number of Prx1 cells 
decreased in both the inner callous and implant suggesting either the presence of bone 
remodeling or a different population of stem cells contributing at later in time. With 
regards to Pax7, previous research has suggested a role in postnatal bone formation. 
However, this study showed that no Pax7 derived cells were seen in bone or the fracture 
callous in the fracture model nor in the implant in the ectopic bone growth model. 
Therefore, it does not appear Pax7 has any role in postnatal bone formation.   
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INTRODUCTION 
Fractures remain one of the most common traumatic injuries with about 6 million 
occurring each year in the United States according to the American Academy of 
Orthopedic Surgeons. Of those 6 million, about 300,000 are slow to heal or do not heal at 
all with traditional methods. Genetic and environmental factors, secondary diseases, and 
mechanisms of injury, i.e how the fracture occurred, may contribute to this slow repair. If 
a fracture fails to heal properly, surgery may be required. Postnatal bone formation 
studies have focused on two different models of bone repair and regeneration: fracture 
healing and distraction osteogenesis (Al-AqL et al., 2011). Fracture repair is a systematic 
response to injury that recapitulates aspects of embryological skeletal development and 
both repairs and restores function and thus acts as a good model in order to investigate 
stem cell recruitment during repair.  Understanding the early mechanisms of post-natal of 
stem cell recruitment and their contribution to the processes of bone formation will allow 
for more specific therapeutics to be developed for non-invasive treatment options for 
patients with fractures that fail to heal properly. 
Bone Development  
Bone formation occurs through one of two processes, endochondral ossification 
or intramembranous ossification. During intramembranous ossification, stem cells within 
the mesenchyme or bone fractures differentiate into osteoprogenitor cells. Further 
differentiation produces osteoblasts which create the extracellular matrix including type I 
collagen and osteoid which becomes mineralized with hydroxyapatite. Once new bone is 
formed, some osteoblasts become osteocytes that are trapped within the bone matrix and 
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continue to regulate bone formation and bone resorption (Anatomy and Physiology). This 
type of bone growth begins in utero and continues into adolescence and is responsible for 
the development of the flat bones of the face, the cranial bones and the clavicle (Anatomy 
and Physiology).  
The second process is endochondral ossification which also begins with the 
recruitment of stem cells then proceeds to cell condensation and differentiation toward 
the chondrocyte linage. The maturing chondrocytes creates a hyaline cartilage that is used 
as a template for the developing bone. As shown in Figure 1, chondrocytes within hyaline 
cartilage become hypertrophic and either enter apoptosis or transdifferentiates to 
osteoblasts (Gilbert, 2006). Angiogenesis of the surrounding cartilage transforms the 
perichondrium into the periosteum producing a thin bone collar around the cartilage 
model. The surrounding extracellular matrix becomes calcified. The group of cells that 
surround the cartilage model differentiate into osteoblasts. As osteoblasts proliferate, the 
bone thickens in length and diameter replacing the remaining cartilage.   
 
Figure 1: Endochondral Ossification. This figure illustrates the stages of endochondral ossification with 
key steps highlighted. Figure modified from Gilbert, 2006.  
New bone similar to fracture healing model 
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Stem Cells 
Stem cells are defined as cells with the ability to replicate themselves and 
differentiate into specific lineages in response to signaling events. Previous research has 
identified three potential sources of skeletal stem cells and signals involved in 
osteogenesis during postnatal fracture repair: periosteum, surrounding soft tissue and 
marrow space at the site of damage (Gerstenfeld et al., 2003). During the early phases of 
healing, skeletal stem cells are activated by inflammation (Khalil et al., 2015). Several 
markers have been identified for skeletal stem cells including Prx1 (Mitchell et al., 2006), 
which this study aims to explore, as well as Grem1+ OCR, LepR+ and CAR cells 
(Mortensen and Hill, 2015). Additionally, Pax7 has been identified as a muscle satellite 
stem cell with potential involvement in postnatal fracture repair (Khalil et al., 2014), and 
thus this study will also explore this stem cell.  
Prx 1 
Prx1 has long been identified as a homeobox gene involved in mesenchyme 
differentiation in mouse models (Cserjesietal., 1992). Prx1 has been shown to act as a 
transcription co-activator and is expressed primarily in undifferentiated regions of 
mesenchyme during embryogenesis, particularly in developing limbs (Norris & Kern, 
2001). Prx1 regulates chondrocyte proliferation and differentiation in bone by increasing 
DNA binding specificity and assists in regulation of bone repair. The inducible Prx1-Cre 
system has been previously used as an important tool for analyzing fracture models as the 
cells of the periosteum are stained and can be identified as stem cells (Murao et al., 
2012). The periosteum plays a crucial role in fracture healing as it is a major source of 
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osteoblasts and chondrocytes.   
Pax 7 
More recently, muscle is being researched as a secondary source of stem cells for 
bone fracture repair. Skeletal muscle and bone are closely linked through common 
mesodermal origins and their developments are highly correlated. Though the 
mechanisms by which muscle supports bone repair remain largely unknown, there is 
evidence that ablation of Pax7 expressing stem cells results in impaired bone regeneration 
in mice (Khalil et al., 2015). Pax7 is an important transcription factor involved in the 
maintenance of skeletal muscle progenitors and myogenic embryogenesis and is 
considered a universal marker of adult skeletal muscle satellite cells. Thus, satellite cells 
and muscle stem cells provide important growth factors needed in the process of 
endochondral ossification (Khalil et al., 2015), but further studies are needed to truly 
define the role of muscle stem cells. 
Fracture Healing  
 Fracture healing is one model in which the role of skeletal stem cells in post-natal 
bone formation is investigated as it is primarily endochondral ossification. Fracture 
healing mechanisms have been divided into four stages, the inflammatory stage, cartilage 
formation stage, cartilage resorption and primary bone formation stage, and the second 
resorptive stage, as shown in Figure 2 below (Schindeler et al., 2008). Fracture repair 
begins with stage one inflammation during which mesenchymal/ progenitor cells are 
recruited to the site of the fracture (Bragdon et al., 2016). Previous research suggests the 
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periosteum is required for successful bone repair as it provides pluripotent cells and a 
response is detected within 24-48 of the fracture (Colnot et al., 2012). Other cytokines, 
including tumor necrosis factor (TNF-a), interleukin 6 and bone morphogenetic protein 2 
(BMP2) recruit inflammatory cells, enhance the cellular matrix and are involved in 
angiogenesis (Ai-Aql et al., 2008).  
 Formation of the cartilage template starts in phase 2. Progenitor cells differentiate 
into chondrocytes and form a soft cartilage callous (Bragdon et al., 2016). This cartilage 
stabilizes the fracture and provides a template for new bone to form. Transitioning to 
stage 3, chondrocytes proliferate and mature, eventually becoming hypertrophic due to 
increased expression of TNF-a. Increased expression of macrophage colony stimulating 
factor, leads to increased activation of its receptor nuclear factor kappa-B ligand and 
osteoprotegerin which causes differentiation of osteoclasts.  This in turn leads to further 
degradation of the cartilage soft callous as osteoblasts are recruited and differentiation 
into a new hard callous. The osteoblasts use the soft callous as a template and replace the 
hypertrophic cartilage with woven bone.  
 The final stage is the second resorptive stage. Osteoclasts resorb the newly 
formed woven bone as osteoblasts replace it with lamellar bone. Similar to the 
inflammatory phase, there is increased expression of TNF-a and BMP2 (Ai-Aql et al., 
2008).  
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Figure 2: Fracture repair model with Cellular Participants. A. Four stage model of fracture healing 
beginning with stage 1 inflammation. The moving on to stage 2 soft callous formation and stage 3 hard 
callous formation. Fracture repair ends with stage four, bone remodeling. B. Anabolic and catabolic model 
of bone healing over time. C. Cellular contributions to fracture repair. Figure modified from Schindeler et 
al., 2008. Cd dxx 
 
Ectopic Bone Formation  
 Ectopic bone formation is another model that can be used to study endochondral 
ossification for post-natal bone regeneration. Methods used for ectopic bone formation 
include subcutaneous implantation of bone marrow derived mesenchymal stem cells 
(BMSCs), intramuscular implantation, or less frequent, kidney capsule implantation 
(Scott et al., 2012). One way to deliver BMSC is through a demineralized bone matrix 
(DBM), as it does not elicit an adverse immune response (Ren et., al, 2017). DBM is 
derived from cancellous bone tissue with the minerals removed and is commonly used to 
stimulate de novo bone formation (Zhu et al, 2017). Clinically, it has been used to treat 
Day 3 
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bone defects in cases of nonunion by inducing new bone formation through endochondral 
ossification (Hexter et al., 2017). When placed on the periosteum, it has large 
regenerative capabilities. However, when placed in the muscle, the bone induction 
capabilities are limited. In order to increase the osteoinductive effects, bone 
morphogenetic protein 2 (BMP2) is added to DBM. BMP2 is a protein in the 
transforming growth factors b (TGF-b) family of secreted growth factors that promotes 
ectopic cartilage and bone formation during development by inducing differentiation of 
skeletal stem cells into chondrocytes and osteoblasts. 
This study aims to examine the stem cell populations that are expressing Prx1 and 
Pax7 lineage and identify the number of positive cells in regions of muscle, bone and 
marrow so that the role of Prx1 and Pax7 in post-natal endochondral osteogenesis can be 
better understood. 
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SPECIFC AIMS  
 
Aim 1: Quantify the background of the transgenic Prx1 CreER reporter animal and the 
transgenic Pax7 CreER reporter animal. 
Aim 2: Investigate and quantify the Prx1 gene that contributes to postnatal bone 
formation, including ectopic bone formation and fracture repair.  
Aim 3: Investigate and quantify the Pax7 gene that contributes to postnatal bone 
formation, including ectopic bone formation and fracture repair.  
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METHODS  
 
Animals  
 All animal studies performed were approved by The Institutional Care and Use 
Committee at Boston University.  The Prx1 CreER-GFP (Kawanami et al., 2010) mouse 
was crossed with the B6. Cg-Gt(ROSA)26sor<tm14(CAG-tdTomato)Hze>/J mouse to 
create Prx1/Ai14 reporter animal. These mice were then crossed with B6,129S7-
Rag1tm1Mom/J (Rag1immunodeficiency) to create a transgenic reporter mouse allowing for 
the implantation of human DBM. A similar strategy was used to create the 
Pax7/Ai14/Rag mouse line with the exception that the Pax7 CreER mouse from Jackson 
Laboratories was used. In total 27 mice were used for this experiment. For the prx1 
control groups, three mice were used for the tamoxifen short term control group, three 
mice were used for the tamoxifen intermediate control group and three mice were used 
for the tamoxifen long term group. Two mice were used for the oil short term control 
group and three mice were used for the oil long term control group. Three mice were 
used for the Cre- tamoxifen long term group and two mice were used for the no injection 
group. For the Pax7 control groups, three mice were used for the no injection group and 
two mice were used for the tamoxifen long term group. For the Prx1 experimental 
fracture group, three mice were used for day five fractures and three mice were used for 
day 23 fractures. For the Pax7 experimental fracture group, three mice were used for the 
day five fractures and two mice were used for the day 23 fractures. For the Prx1 
experimental implant group, three mice were used for day 16 implants in the periosteum 
and one mouse was used for day 16 implants in the muscle. One mouse was used for the 
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day 31 implants in the periosteum and one mouse was used for the day 31 implants in the 
muscle. For the Pax7 experimental implant group, one mouse was used for day 16 in the 
periosteum and no mice were used for day 31. Both male and female mice were used. 
Mice were about 3 months old at the time of injections.  
 
Tamoxifen Injections 
Tamoxifen (10mg/ml) solutions were prepared by combining 12 mL of corn oil 
with 120 mg of tamoxifen under a chemical safety hood. In order to fully dissolve the 
tamoxifen in corn oil, the solution was sonicated for 4 rounds of 15 minutes and checked 
for full dissolution. The dissolved solution was sterile filtered using a syringe filter 
(Corning Incorporated) and a 10-mL syringe and aliquoted into 2 mL vials. The vials 
were stored at -80 ̊C. Mice received intraperitoneal injections at 10 µL/g of their body 
weight. Animals received corn oil as part of control experiments. Control mice were 
placed into either a short term, intermediate, or long-term group. In the short-term group, 
mice received 2 rounds of either tamoxifen or corn oil injections, 48 hours apart and then 
were harvested 3 days after the second injection. In the intermediate group, mice received 
2 rounds of tamoxifen, 48 hours apart and then were harvested at about 17 after the 
second tamoxifen injection. In the long-term group, mice received 2 rounds of tamoxifen 
or corn oil injections, 48 hours apart and then were harvested at least 28 days after the 
second tamoxifen injection.  
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Surgery Preparation 
 Experimental animals were first anesthetized using a combination of 4% 
isoflurane and oxygen in an anesthesia chamber. Once anesthetized, the animal was given 
continuous 2% isoflurane and oxygen through a nose cone to maintain sedation. The mice 
then received subcutaneous injections of 0.01 mL of 2.27% Baytril as an antibiotic and 
0.1 mL of Buprenex ®. The surgical site was shaved and cleaned with Betadine.  
Fracture surgery 
 Fracture surgery was performed as previously described in Lybrand et al., 2015. 
In summary, the distal end of the femur was exposed with a #15 scalpel blade. An entry 
site was created using a 27-guage syringe in the center of the trochlear groove of the 
femur. The tip of the syringe was buried into the groove to create a pathway and then 
removed. A 25-guage spinal needle was inserted into the groove and cut at the distal end 
of the femur with wire cutters. The incision was then closed with a 5-0 gut suture and the 
animal was moved to a fracturing device. A fracture was generated by dropping a 
predetermined weight with a blunt blade, large enough to generate a fracture, onto the 
mid-diaphyseal shaft of the right femur. To ensure fracture and proper placement of the 
pin, an x-ray was taken using a dental X-ray machine with settings of 70 kV and 0.10 
seconds. The weight of the mouse was recorded and the mouse recovered on a heating 
pad until it woke up and was then placed back into the cage.  
DBM Surgery 
 DBM surgery was performed as described in Bragdon et al., 2017. The surgery 
  12 
was performed in two parts, with a femoral surface implant and a muscle implant. In 
summary, for the femoral surface implant, the femur was exposed by making a 1.5 cm 
incision along the right femur from the greater trochanter towards the knee joint, and the 
fascial plane was cut. Human DBM (50 mg) was surgically implanted. The fascial plane 
incision was then closed with 6-0 plain gut sutures followed by suturing of the skin with 
5-0 plain gut sutures. Muscle implant surgery is similar to as described above. Skin and 
fascia were cut to expose the muscle in the upper left thigh. DMB was placed in a pouch 
between the medial gluteal and femoral quadriceps. Fascia and skin were sutured similar 
to above.  The weight of the mouse was recorded and the mouse recovered on a heating 
pad until it woke up and was then was placed back into the cages. 
Harvest 
Harvests were done on specified dates post-surgery as described in Figure 3. Mice 
received the first tamoxifen injection on day -2 and the second injection on day 0. Mice 
in the day 3 control group were designated as short term meaning Prx1 expressing cells 
were labeled and harvested three days post the second injection. Mice in the day 17 
control harvest group were designated as intermediate as they were harvested 17 days 
passed the second injection. Mice in the day 28-31 control group were designated as long 
term for they were harvested 28-31 days since the second injection. Controls were set up 
in order to analyze whether there would be a difference in stem cell recruitment at 
various time points. Also, on days 28-31, the experimental groups received either fracture 
or implant surgery. Mice in the fracture groups were harvested on either post-operative 
date (POD) day 5 or POD 23. Mice in the DBM implant group were harvested on either 
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POD 16 or POD 31. Note that mice in the experimental groups followed the long-term 
stem cell recruitment control group. 
 
Figure 3: Harvest schedule. This image shows the injection and harvest schedule for both control and experimental 
groups. Arrows represent injection dates and stars represent harvest dates. POD = post-operative date. A. Timeline of 
total number of days. B. Timeline with in reference to surgery as day 28-31, with subsequent days counted as post-
operative time points. 
Harvests were performed in lab. Mice were euthanized by carbon dioxide 
inhalation followed by cervical dislocation.  Harvest weight was recorded. An x-ray was 
taken to ensure the presence of a fracture callous or ectopic bone using Faxitron MX-20 
Specimen Radiography System which was set to 30 kV for 40 seconds (Figure 4). The 
film used was Kodak Biomax XAR Scientific Imaging Film. The desired tissues were 
then harvested and fixed in 4% paraformaldehyde (PFA). 
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Figure 4: X-rays of Fracture Callous and Implant. A. This picture shows an x-ray of a day 21 fracture callous. B. 
This picture shows an x-ray of a muscle implant day 16.  
 
4% Paraformaldehyde and Sample Fixation 
Under the fume hood, 150 mL of dH2O was heated to about 60°C on a hot plate. 
10 g of paraformaldehyde was added to the heated dH2O. About 2-4 drops of 10N NaOH 
was added until the solution turned clear. The solution was then removed from heat and 
allowed to cool to room temperature. The pH was adjusted to about 7.4 using NaOH or 
HCl and confirmed with a pH meter. Twenty-five milliliters of 1M 10x PBS was added to 
the flask and then water was added to bring the volume up to 250mL. The solution was 
aliquoted into 15 mL tubes and stored at-80 ̊C. Samples were fixed 48-72 hours at 4°C 
followed by decalcification. 
Decalcification  
 
Samples were first washed with 1x PBS 3x for 10 minutes. Samples where then 
placed in mesh bags, labeled and stapled closed. They were then immersed in a jar with 
14% Ethylenediamine Tetraacetic Acid (EDTA) and covered in foil to protect light 
sensitive samples. A stir bar was added and the jar was placed on a stir plate for 1-2 
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weeks. After about one week, a 27-gauge syringe tip was used to probe the sample to 
confirm the bone had been decalcified.   
 
Frozen Histology 
Once the samples had been fully decalcified, they were removed from EDTA and 
washed 3x with 1x PBS for 10 minutes. Samples were then placed back in their 
respective 15 mL vials with 7.5 mL of 7.5% sucrose solution with PBS and 7.5 mL of 
optimum cutting temperate (OCT) compound. The vials were placed on a shaker at 4°C 
overnight. The next day samples were removed from the shaker, drained, and refilled 
with 7.5 mL of 30% sucrose solution in PBS and 7.5 mL of OCT. They were placed back 
on the shaker at 4°C overnight. On day three, the solution was removed and 7.5 mL of 
50% sucrose and 7.5 mL of OCT was added to the samples and placed back on the shaker 
overnight. Samples were embedded by immersing the sample into a basin filled with 
tetrafluorethane surrounded by liquid nitrogen for about one minute until the sample was 
completely frozen. Samples were stored in -80 ̊C until sectioned.  
Blocks were sectioned on a Reichert-Jung Cryocut 1800 at 8-10 µm, except for a 
few samples where noted that were sectioned at 10-12 µm due to the size of the sample. 
Slides were then mounted on Superfrost Plus slides and air dried at room temperature 
before storage at -20 °C.   
To begin cover-slipping, cut sections were immersed in 1X PBS for five minutes 
twice and quickly rinsed with ddH2O. Sections were laid out to air dry and cover-slipped 
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using Molecular Probes ProLong © Gold Antifade reagent with DAPI. Air bubbles were 
carefully removed.   
Imaging  
 Sample images were taken using Olympus BX5 microscope and image processing 
and quantification was carried out using Cell Sens software in the dark. The microscope 
was first calibrated to stage limits and camera angle. Samples were placed under the 
microscope and the appropriate filter was set on the microscope, 2 for dTomato and 6 for 
Dapi. Photomicrographs were acquired (Olympus BX51; Olympus America, Inc., Center 
Valley, PA) using a 10x objective and automated stage (CellSense Dimensions, version 
4.1.0.0, Olympus America). Image exposure time for Dapi filter was 10.5 ms and for 
dTomato filer was 8.3 ms, though slight adjustments were made from sample to sample. 
Dapi filter was used to capture the nuclei of all cells and dTomato was used to identify 
only Ai14 reporter positive cells.   
Cell counting  
In order to calculate the ratio of dTomato cells to total cell nuclei, both Prx1 and 
Pax7 samples were split into multiple regions of interest. These are as follows based on 
figures 5-7.  Regions of interest were used to count cells because counting the entire 
sample took too much time and allowed for comparison of medial and lateral regions to 
determine difference in the number of dTomato positive cells within each section. 
Regions of interest were determined relative to the femoral head and the size was 
determined based on the amount of muscle, bone, and marrow space available such that 
folds, smudges and other artifacts would not be included in the counted regions. 
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Figure 5: Cell Counting for Control Samples. This figure represents the general schematic followed for 
dividing regions of interest for cell counting for control samples. Blue outlines represent muscle and the red 
outline represents bone. The purple represents the marrow space. The green boxes represent regions of 
interest. 
 
Within the muscle, eight regions of interest were counted and added together. 
Within the bone, one region of interest was counted within each division. A ratio of the 
amount of counted Prx1 derived cells to total number of nuclei were calculated to create a 
percentage of labeled cells within the areas of interest. These regions of interest were 
then transferred over to other slides from the same sample to maintain consistency. In 
order to create the most accurate area for counting, Ai14 exposure was set to 50 artificial 
fluorescent units and Dapi exposure was set to 20 artificial fluorescent units for control 
samples. Exposure for Ai14 was higher to minimize false positives. For experimental 
samples, Prx and Dapi exposures were set similar to the controls with Ai14 set to 50 and 
Dapi set to 20.  The same settings were used to count Pax7 samples.  
 For fractures, cell counting was done according to Figure 6. Callous sections were 
divided into four outer quadrants and one central quadrant.   
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Figure 6: Cell Counting for Fracture Samples. This figure represents the general schematic followed for 
dividing regions of interest for cell counting for fractures samples.  
 
For implants, cell counting was done according to Figure 7 below. Implants were 
counted separately from bone.  
 
 
Figure 7: Cell Counting for Implant Samples. This figure represents the general schematic followed for 
dividing regions of interest for cell counting for implant samples. 
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RESULTS 
 
The goal of this study was to quantify and compare the skeletal stem cell 
populations recruited during postnatal bone formation and repair using Prx1 and Pax7 as 
stem cell markers.  
Cre+ Mouse Models 
 The Prx1CreER-GFP-RosaAi14 mice were used for this study and allowed for the 
conditional and inducible control of the Cre recombinase activity through Tamoxifen. 
When Tamoxifen is given, it binds to the estrogen receptor that is bound to Cre. The 
entire complex then translocates into the nucleus and initiates removal of the stop codon, 
allowing expression of the dTomato gene. dTomato will then label all progenitor cells 
and progeny red which can be visualized under a microscope. (Maes et. al 2007). 
 
Figure 8: Cre Recombinase Model. This figure demonstrates the interaction of Cre recombinase model in 
the presence of Tamoxifen. A. When there is no Tamoxifen, there is no expression of dTomato due to 
expression of the stop codon. B. When Tamoxifen is present, Cre moves into the nucleus, the stop codon is 
removed and dTomato is expressed. Figure modified from Maes et. al 2007.  
 
A B 
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Establishing the leakiness and baseline of Prx1/Ail4/Rag Mouse Model 
 Previous work identified and traced the Prx1 lineage through fracture repair and 
ectopic bone formation (Bernie thesis). Asides from the periosteum, Prx1 cells were also 
identified in the marrow, cortical bone and muscle and thus these regions were also 
investigated. In order to present a more comprehensive analysis of the fracture and 
ectopic bone results, the leakiness and baseline of the Prx1/Ai14/Rag must be established 
as it is currently unknown. This will allow for a more comprehensive analysis of the 
fracture and ectopic bone results.  In order to evaluate the leakiness of this model, control 
mice received either oil injections short term, oil injections long term or received no 
injections. Mice in the oil short term group were harvested on day 3. Mice in the oil long 
term group were harvested on days 28-31. Mice that received no injections would be 
comparable to day -2 mice. Cre negative mice were also studied to determine leakiness of 
the Cre recombinase system and were given tamoxifen injections. These mice were 
placed in the tamoxifen long group and harvested on days 28-31. All control mice that 
received injections received the same two rounds of injections on days -2 and 0. The 
short term, intermediate, and long-term terminology refers to the amount of time after 
injections the mice were harvested. Figure 9 is a close-up image in order to show regions 
of interest and how the computer counts cells. Each yellow dot represents a counted cell. 
Figures 10-13 below show leakiness controls and figures 14-18 show baseline controls 
for Prx1. This quantitative analysis is shown below in graph 1. For mice in the oil short 
term group, about 7% of the total cells were positive in the muscle, 14% were positive in 
the bone and 7% were positive in the marrow. For mice in the oil long term group, 8% of 
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the total cells were positive in the muscle, 21% were positive in the bone and 8% were 
positive in the marrow. For mice in the Cre+, no injection group, 9% of the total cells 
were positive in the muscle, 11% were positive in the bone and 7% were positive in the 
marrow. Lastly, in the Cre negative, tamoxifen long term group, 9% of the total cells 
were positive in the muscle, 16% were positive in the bone and 5% were positive in the 
marrow. 
 In order to evaluate the baseline of this model, control mice were split into 
Tamoxifen injection groups and placed in either the short term, intermediate, or long-
term category. These time points were chosen in order to investigate whether there is a 
difference in the amount of stem cell recruitment at these time intervals. Short term mice 
were harvested on day 3, intermediate mice were harvested on day 17 and long-term mice 
were harvested on days 28-31 (Figure 3). This quantitative analysis is shown below in 
graph 2. For mice in the Cre+, TM short term group, 2% of the total cells were positive in 
the muscle, 3% were positive in the bone and 2% were positive in the muscle. For mice 
in the Cre+, intermediate group, 10% were positive in the muscle, 23% were positive in 
the bone and 17% were positive in the marrow. Lastly in the Cre+, long term group, 14% 
were positive in the muscle, 20% were positive in the bone and 11% were positive in the 
marrow.  
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Graph 1: Prx1 Leakiness: Graph represents percentage of positive dTomato cells in Prx1 control groups 
in muscle, bone and bone marrow in order to determine leakiness of the cell. Control groups are Cre+ with 
no injections. Cre+ with oil injection short term and long term. And Cre- mouse models.  
 
 
Graph 2: Prx1 Baseline: Graph represents percentage of positive dTomato cells in Prx1 control groups in 
muscle, bone and bone marrow in order to determine baseline of the cell. Control groups are Cre+, TM 
short term harvested on day 3, Cre+, TM intermediate harvested on day 17, and Cre+, TM long term 
harvested on days 28-31.  
 
  
 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
Muscle Bone Marrow
Prx1 Leakiness
Cre +, No Injections Cre-, TM Long Term Oil Long Term Cre+, Oil Short Term
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
Muscle Bone Marrow
Prx1 Baseline
Cre+, TM Day 3 Cre+, TM Day 17 Cre+, TM Day 28-31
  23 
  
 
 
Figure 9: Close-up Image of Cell Counting Region of Interests. 10x stitched closeup cell counts. ROIs 
outlined. Counted cells appear yellow within ROIs. A. DAPI stained nuclei. B. Prx1 positive stained cells. 
A 
B 
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Figure 10: Cre- Control. 10x stitched overview of Cre- controls with cell counts. ROIs outlined. White 
dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI stained nuclei. B. Prx1 
positively stained cells.  
 
  
Figure 11: No Injection Control. 10x stitched overview of no injection control with cell counts. ROIs 
outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI stained nuclei. 
B. Prx1 positively stained cells.  
 
A B 
A B 
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Figure 12: Oil Injection Short Term Control. 10x stitched overview of day 3 oil injection short term 
control with cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within 
ROIs. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
 
 
 
  
Figure 13: Oil Injection Long Term Control. 10x stitched overview of day 28-31 oil injection short term 
control with cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within 
ROIs. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
 
A B 
A B 
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Figure 14. Tamoxifen Short Term Control: 10x stitched overview of day 3 Tamoxifen injection control 
with cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. 
A. DAPI stained nuclei. B. Prx1 positively stained cells.  
 
 
 
  
Figure 15: Tamoxifen Intermediate Control: 10x stitched overview of day 17 Tamoxifen injection 
control with cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within 
ROIs. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
 
A B 
A B 
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Figure 16: Tamoxifen Long Term Control: 10x stitched overview of day 28-31Tamoxifen injection 
control with cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within 
ROIs. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
 
Similarly, the leakiness of the cell and the baseline response were also analyzed 
for Pax7. No injections control group was used to determine the leakiness while 
Tamoxifen long term was used to determine the baseline response of the Cre system.  As 
show in graph 3, only about 2% of the total nuclei stained positive for pax7 in the muscle, 
0.03% were positive in the bone and no cells were stained in the marrow. Figure 17 
shows no injection control images. Note how the pax7 bone does not appear in the image, 
hence why there were no positive cells seen in the bone or the marrow.  
 
 
Graph 3: Pax7 Leakiness: Graph represents percentage of positive dTomato cells in Pax7 control groups 
in muscle, bone and bone marrow in order to determine leakiness of the cell. Control group used was no 
injections.  
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Figure 17: Pax7 No Injection Control: 10x stitched overview of no injection control with cell counts. 
ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI stained 
nuclei. B. Pax7 positively stained cells.  
 
Pax7 baseline response was also analyzed. As show in the graph 4 below, only 
about 2% of the total number of nuclei stained positive for pax7 cells, similar to the no 
injection control. No positive cells were seen in the bone or marrow. Figure 18 shows 
tamoxifen long term control group.  
 
A B 
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Graph 4: Pax7 Baseline: Graph represents percentage of positive dTomato cells in Pax7 control groups in 
muscle, bone and bone marrow in order to determine baseline of the cell. Control group used tamoxifen 
long term.  
 
 
 
         
Figure 18: Pax7 Tamoxifen Long Term Control: 10x stitched overview of tamoxifen long term control 
with cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. 
A. DAPI stained nuclei. B. Pax7 positively stained cells.  
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Recruitment of Prx1 and Pax7 derived cells during fracture repair 
Fracture surgery was used to investigate the recruitment of Prx1 and Pax7 stem 
cells to the area of the injured bone and surrounding muscle during injury.  Animals 
received tamoxifen long term (28-30) day washout period between the last injection and 
surgery.  Two time-points were obtained, POD 5 which represents the early phase of 
fracture repair with stem cell recruitment and chondrogeneis and POD 23 which 
represents the later phase of fracture repair with bone and remodeling. Three areas of 
tissue were investigated for Prx1 positive cells, bone, muscle and bone marrow, since 
these areas were identified previously to house Prx1 positive cells (Bennie thesis). 
Figures 19-22 are 10x stitched overview images of the fracture models with callous 
formation and show regions of interest for areas counted.  DAPI labels nuclei blue and 
Prx1 derived or Pax7 derived positive cells are labeled red. 
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Figure 19: Day 5 Prx1 Fracture Model: 10x stitched overview of day 5 fracture model with cell counts. 
ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI stained 
nuclei. B. Prx1 positively stained cells.  
 
         
 
             
 
 
 
 
 
A B 
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Figure 20: Day 23 Prx1 Fracture Model: 10x stitched overview of day 23 fracture model with cell 
counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI 
stained nuclei. B. Prx1 positively stained cells.  
 
 
A B 
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Figure 21: Day 5 Pax7 Fracture Model: 10x stitched overview of day 5 fracture model with cell counts. 
ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI stained 
nuclei. B. Prx1 positively stained cells.  
 
  
Figure 22: Day 23 Pax7 Fracture Model: 10x stitched overview of day 23 fracture model with cell 
counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. A. DAPI 
stained nuclei. B. Prx1 positively stained cells.  
  
Quantitative data was obtained by counting the total number of positive Prx1 and 
Pax7 cells within each region of interest and the total number of nuclei within that region. 
A B 
A B 
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The ratio was then calculated and Graph 5 shows the percentage of positive Prx1 and 
Pax7 cells in muscle, bone, outer callous and inner callous. The muscle compartment 
showed only 8% and 12.5% for POD 5 and 23 respectively and the bone showed a 
modest 30% and 18% Prx1 derived cells for POD 5 and 23, respectively. The highest 
percentage of Prx1 derived cells occur in the outer callous 61% for both POD 5 and 23. 
Similarly, 69% of cells were Prx1 derived within the inner callous at POD 5 fracture, 
however it decreased to 44% at POD 23. For Pax7 samples, the highest percentage of 
Pax7 derived cells occurred within the outer callous at POD 5 fracture, although it was 
only 8% of the total number of cells.  No positive cells were seen within the inner callous 
at POD 23. This is as expected because Pax7 labels muscle progenitor cells and should 
not be seen within bone or the fracture callous. 
 
 
 
  
Graph 5: Fracture Model: A. Graph represents percentage of positive dTomato cells in muscle, bone, 
outer callous and inner callous. B. Graph represents percentage of positive cells in muscle, bone, outer 
callous and inner callous. Note the scale difference between Prx1 and Pax7 graphs.  
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Recruitment of Prx1 and Pax7 derived cells during DBM implants 
The second method used to analyze stem cell recruitment during postnatal bone 
formation was through the use of DBM induced ectopic bone model.  Two surgeries were 
performed; in the first, the DBM implant was placed onto the periosteal surface. In the 
second, the DBM implant with BMP2 was placed within the muscle near the femur. Mice 
received tamoxifen with long term washout, similar to the fracture study and were 
harvested on either day 16 or day 31 post-surgery. The difference in time points 
correlates with known phases of DBM induced ectopic bone formation, where day 16 
shows bone formation and day 31 shows bone remodeling. Figures 23-26 are 10x stitched 
overview images of the implant models. Figure 27 shows the close-up overlay of Prx1 
derived positive cells to the total number of nucleus within a periosteal implant. Figure 
28 shows the Prx1 positive red ring around the muscle implant. This ring is not seen in 
the periosteal implant. 
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Figure 23: Day 16 Prx1 Periosteal Implant Model: 10x stitched overview of day 16 implant model with 
cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. White 
arrows point to implant location. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
 
  
Figure 24: Day 16 Prx1 Muscle Implant Model: 10x stitched overview of day 16 implant model with cell 
counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. White 
arrows point to implant location. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
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Figure 25: Day 16 Pax7 Periosteal Implant Model: 10x stitched overview of day 16 implant model with 
cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. White 
arrows point to implant location. A. DAPI stained nuclei. B. Pax7 positively stained cells.  
 
 
 
  
Figure 26: Day 31 Prx1 Periosteal Implant Model: 10x stitched overview of day 31 implant model with 
cell counts. ROIs outlined. White dash lines outline bone. Counted cells appear yellow within ROIs. White 
arrows point to implant location. A. DAPI stained nuclei. B. Prx1 positively stained cells.  
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Figure 27: Day 31 Prx1 Periosteal Implant Model Overlay: 20x stitched overview image of day 31 
periosteal implant. Note ratio of positively stained red Prx1 cells to total number of nuclei stained blue.   
 
 
Figure 28: Day 16 Prx1 Muscle Implant Model Closeup: 20x stitched overview image of day 16 muscle 
implant. Note red Prx1 positive ring around the muscle implant. This is not seen in the periosteal implant. 
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Quantitative data was obtained by counting the total number of Ai 14 positive 
cells within each region of interest and comparing it to the total number of nuclei within 
that region. Implants were separated into two categories, periosteum implants and muscle 
implants. Graph 6 below shows the results for the periosteal implant for both Prx1 and 
Pax7 and graph 7 below shows the results for the muscle implant for Prx1. For the 
periosteal implant, 51% of cells were Prx1-derived positive cells at POD 16, however it 
decreased to 30% at POD 31. The bone consisted of 44% of Prx1 derived cells and this 
did not change with time. The largest percentage of Prx1-derived positive cells for day 16 
muscle implants occurred within the bone and for day 31 muscle implants occurred in the 
implant. Percentages for day 16 implant and bone were similar for the periosteum 
implants. The response in marrow for muscle implants was about 10%, which is lower 
than the response in marrow for periosteum implants (20%). For Pax7 derived cells, the 
highest percentage was quantified in the muscle as expected because Pax7 is a muscle 
progenitor cell. However, this was only 4.96% of the total number of cells and therefore 
could be due to background and not a response to the DBM implant.   No positive cells 
were seen in the bone, marrow or implant as expected. 
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Graph 6: Prx1 Implants: A. Graph represents percentage of positive dTomato cells in muscle, bone, outer 
callous and inner callous for periosteal implants. B. Graph represents percentage of positive cells in muscle, 
bone, outer callous and inner callous for muscle implants.  
 
 
Graph 7: Pax7 Periosteal Implants: Graph represents percentage of positive Pax7 cells in muscle, bone, 
outer callous and inner callous for periosteal implants.   
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DISCUSSION  
Prx1 and Pax7 Leakiness and baseline of Cre system 
 
Previous work identified and traced the Prx1 lineage through fracture repair and 
ectopic bone formation. However, leakiness and baseline of the Prx1/Ai14/Rag model is 
unknown. Fully characterizing the Prx1/Ai14/Rag model will allow for a more 
comprehensive analysis of the fracture and ectopic bone results.   
 The Cre negative mice do not express the Cre protein and therefore no 
recombinase system to activate the reporter resulting in a lack of labeled cells.  Similarly, 
the control groups that received corn oil injections should not express the reporter, 
dTomato, due to no translocation of Cre to the nucleus. However, according to the results 
shown here, about 6% of cells were labeled red in the muscle11% of cells labeled in bone 
and 7% of cells labeled in bone marrow for the Cre- control group.  This was not 
expected.  One possibility is that the mice were genotyped wrong for Cre and actually 
expressed Cre. Further studies would need to check for correct genotyping and reanalyze 
the samples. Another possibility is that these mice were older and thus were expressing 
stem cells for bone regeneration. More surprising was that Cre positive animals treated 
with corn oil long term showed even higher levels of labeled cells in the bone and 
marrow, 20.50%, and 7.73%, respectively. It is possible that the corn oil treated animals 
were exposed to tamoxifen either by tamoxifen contaminated corn oil or being housed 
with tamoxifen treated animals. Addition animals should be enrolled to confirm this. It is 
likely that there is some leakiness within the Cre reporter system resulting in some 
labeling of stem cells.  
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The tamoxifen long term washout group showed high levels of labeled cells with 
14.47% of cells in the muscle, 19.65% of cells in the bone and 10.71% of cells in the 
marrow. This was expected as the harvest date was twenty-eight days from the time of 
the last injection. So not only were the Prx1 positive cells labeled, but the time allowed 
for expansion and/or differentiation of those stem cells.  This group showed more labeled 
cells than the Tamoxifen short term and intermediate groups which were harvested 3 and 
17 days after the last injection. These cells did not have as much time to 
expand/differentiate as the Tamoxifen long term group. 
For pax7, both the leakiness and baseline appear to be minimal to none. The 
highest percentage of positive cells seen was in the muscle (about 2%) for both the no 
injection control and the tamoxifen long term control. This is not surprising since pax7 is 
a muscle progenitor stem cell marker. There was a 0.03% response seen in the bone for 
the no injection control. This could represent the leakiness of the Pax7 CreER reporter 
system. Therefore, the leakiness is minimum while the baseline of Pax derived cells is 
low.   
Once the baseline of Prx1 and Pax7 derived cells was established using the 
tamoxifen long term, the data gathered from both the fracture models and implant models 
were analyzed.  
Prx1 and Pax7 Recruitment During Callous Formation 
 As mentioned above, previous research has identified Prx1 derived cells, largely 
concentrated in the periosteum and callous, during postnatal fracture repair (Murao et al., 
2013). This study furthered investigated the Prx1 stem cell lineage in relation to different 
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time points post fracture surgery. In addition, previous research has suggested that Pax7 
muscle satellite cells may also be involved in postnatal fracture repair (Khalil et al., 
2015). Tamoxifen injections were done following the tamoxifen long term schedule in 
order to target the pre-existing skeletal stem cell population that is recruited to the callous 
site during fracture repair and not the population of cells where Prx1 expression is 
induced due to injury. Time points investigated were day 5 and day 23 post-surgery in 
order to explore whether stem cell populations differ between the two-time points. At day 
5, we expected an increase of stem cell recruitment after the initial injury, as 
inflammatory factors recruit chondrocytes to the area of injury. As expected, Prx1 
derived cells were recruited to the site of fracture and contributed to callous formation. 
However, Pax7 samples did not appear to have a role in fracture repair as there were no 
labeled cells recruited to either the bone or the callous for either time point. Therefore, it 
appears that Pax7 does not have a role in postnatal fracture repair. It would be worth 
investigating whether physical damage to the muscle would increase Pax7 recruitment 
and comparing those results to femur fractures with the surrounding muscle damaged to 
see if an increase in Pax7 recruitment can be stimulated.  
 More intriguing was the result comparing the outer and inner callous at day 5 and 
day 23 for the Prx1 fracture group. For day 5 fractures, the number of labeled cells in the 
inner callous is over 60%. However, by day 23, it decreased to 40% in the number of 
labeled cells.  This may be due to the fact that at the later time point, the phase of stem 
cell recruitment is past and bone remodeling is occurring. Suggesting that the early 
recruited stem cells do not contribute as much to the bone remodeling phase as the earlier 
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phase and that there may be another population of cells being recruited to this site. It is 
unclear as to what population of cells are being recruited.  Furthermore, the percentage of 
labeled cells at day 23 in the outer callous did not show this decrease as the inner callous. 
It actually showed a similar percentage of labeled cells as day 5 outer callous. This 
suggests that bone remodeling may start within the inner callous and work its way 
outwards. It would be worth investigating an even later time point to see if the percentage 
of labeled cells in the outer callous would start to decrease as well. Another idea is that 
the population of cells recruited during bone remodeling within the inner callous is a 
different population than the population in the outer callous.   
Prx1 and Pax7 Recruitment During Ectopic Bone Formation 
 Similar to the fracture model, the recruitment of Prx1 and Pax7 derived cells was 
investigated during ectopic bone formation. Ectopic bone formation follows a similar 
development pattern to endochondral ossification and thus can provide insights into stem 
cell recruitment mechanisms (Zhu et al, 2017). Both periosteal and muscle implants were 
investigated to determine whether location of the implant would affect stem cell 
recruitment. Time points were either day 16 (peak bone) or day 31 (bone remodeling).  
Results for ectopic bone formation followed a similar pattern to fracture callous 
formation. For the Prx1 model, there was a decrease in the percentage of Prx1 derived 
cells for day 31 implants compared to day 16 in the ectopic bone tissue although the 
decrease seen with the muscle implant was minimal. This decrease was also observed 
within the muscle and bone compartments. This is in agreement with our fracture model, 
that the later time points of bone remodeling is not primarily occurring with the Prx1 
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derived cell population that is first recruited to site of post-natal bone formation, 
suggesting other population.  
Implants were separated into periosteum implants and muscle implants in order to 
investigate whether, knowing that a large majority of the Prx1 derived stem cells 
originate in the periosteum. The periosteal implant did show more recruitment/expansion 
of the Prx1 derived cells compared to the muscle implant at day 16. Interestingly, by day 
31, both implant locations showed similar percentage of Prx1 derived cells. This suggests 
that the periosteal implant is highly dynamic with cell populations changing while the 
muscle implant is not. It is also worth noting that the muscle implants have a ring around 
the implant that stains red (Figure 28), which is not seen in the periosteal. This ring was 
included and contributed to the “implant” compartment cell counts for the muscle 
implants but it would be worth splitting the implant into an inner region and an outer 
region and analyzing whether the cell counts differ. There seems to be a higher response 
in the surrounding muscle of muscle implants at day 16 (37%) than in the surrounding 
muscle of periosteum implants at day 16 (28%) as seen within the muscle compartment.  
 Similar to the fracture model, Pax7 derived cells were only positive within the 
muscle and there were no positive cells seen in bone, marrow or the implant. Therefore, 
Pax7 derived stem cells are not involved in ectopic bone growth either. The positive cells 
seen within the muscle may be due to background noise as they were only 4.96% of the 
total number of cells within the area. Given that these cells did not yield positive results 
in the bone, marrow and implant, day 31 implants were not done.  
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